Journal of Immunology Research / 2017 / Article / Tab 3

Review Article

Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review

Table 3

The blockade of immune checkpoints in prostate cancer.

DrugAgent description

IpilimumabThe inhibition of CTLA-4
Pembrolizumab (previously known as MK-3475 and lambrolizumab)The inhibition of PD-1
PidilizumabThe inhibition of PD-1

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.